DOCSLIB.ORG

October 2, 2020 | 8:30 A.M.—5:30 P.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
October 2, 2020 | 8:30 A.M.—5:30 P.M in Tumor Immunology and Cancer Immunotherapy Conference October 2, 2020 | 8:30 a.m.—5:30 p.m. Time Title Speaker Neli Ulrich, PhD 8:30 a.m. Welcome Executive Director, Comprehensive Cancer Center Huntsman Cancer Institute Antitumor Immune Responses Induced by PD-1 Antoni Ribas, MD, PhD 8:45 a.m. Blockade Therapy University of California Los Angeles Rational Tumor and Immune Cell Treatment Daniel Peeper, PhD 9:30 a.m. Combinations: A Functional Genomics Approach Netherlands Cancer Institute 10:15 a.m. Break Sandra D’Angelo, MD 10:30 a.m. Cancer Testis Antigens as Therapeutic Targets in Sarcoma Memorial Sloan Kettering Cancer Center New T Cell Receptors and Targets by Dissection of Andrew Sewell, PhD 11:15 a.m. Successful Cancer Immunotherapy Cardiff University Noon Lunch CAR T Cell-Based Combination Immunotherapy for Prasad S. Adusumilli, MD, FACS 1 p.m. Solid Tumors Memorial Sloan Kettering Cancer Center Overcoming Resistance to Immune Checkpoint Blockers Zihai Li, MD, PhD 1:45 p.m. by Targeting GARP-TGF-Beta Pathway The Ohio State University 2:30 p.m. Break From the Clinic to the Lab: Investigating Mechanisms of Padmanee Sharma, MD, PhD 2:45 p.m. Response and Resistance to Immune Checkpoint Therapy MD Anderson Cancer Center The Role of Gut and Tumor Microbiome in Response Jennifer Wargo, MD, MMSc 3:30 p.m. to Cancer Therapy MD Anderson Cancer Center 4:15 p.m. Break Ira Mellman, PhD 4:30 p.m. Mechanistic Basis of Cancer Immunotherapy Genetech Alana Welm, PhD 5:15 p.m. Closing Remarks Co-Director, Cell Response and Regulation Program Huntsman Cancer Institute SPEAKERS Prasad S. Adusumilli, MD, FACS Memorial Sloan Kettering Cancer Center Dr. Adusumilli is a thoracic surgeon with expertise in the management of cancers in the chest, including primary (lung cancer, mesothelioma, thymoma, esophageal cancer) and metastatic tumors. Dr. Adusumilli’s laboratory research, supported by NIH RO1 and DoD awards, focuses on tumor immunology and chimeric antigen receptor (CAR) T cell-mediated immunotherapy for cancers. Over the years, he and his lab have developed clinically relevant solid tumor mouse models and modeled regional delivery of novel biological therapies, including oncolytic viruses and immune cells in these models. This research has yielded mechanistic data that has been translated and is now in clinical trials for patients with lung cancer, mesothelioma, and breast cancer. His ongoing research focuses on combination immunotherapy to reactivate both CAR T cell and endogenous immunity by use of cell-intrinsic and extrinsic checkpoint blockade strategies; combination of CAR T cells with anti-PD1 agent is now in phase II clinical trial. As Head of solid tumor cell therapy in the Cellular Therapeutics Center at the Memorial Sloan Kettering Cancer Center, Dr. Adusumilli conducts and coordinates cell therapy clinical trials for solid tumor patients. Sandra D’Angelo, MD Memorial Sloan Kettering Cancer Center Dr. D’Angelo is a medical oncologist at Memorial Sloan Kettering Cancer Center dedicated to developing immunotherapy for the management of sarcoma and Merkel cell carcinoma. Specifically, she is interested in understanding the efficacy of various immunotherapies and elucidating biomarkers predictive of response in patients with these rare tumors in partnerships with basic scientists, cooperative groups, and industry. Dr. D’Angelo leads the sarcoma-specific translational research program in immunotherapy at Memorial Sloan Kettering Cancer Center to systematically explore novel combination strategies with checkpoint blockade and adoptive T-cell therapy. This disease-specific work ties in, and is informed by, her role in Early Drug Development and Cellular Therapeutics Core where she participates in early phase immunotherapy studies exploring novel agents across solid tumors. Zihai Li, MD, PhD The Ohio State University Dr. Li is the founding director of the Pelotonia Institute for Immuno-Oncology (PIIO), at the Ohio State University Comprehensive Cancer Center and is a cancer immunologist, physician scientist, and board- certified medical oncologist. Dr. Li’s research interests in the last 20 years have primarily been in the field of chaperone biology, immune tolerance, and cancer immunology, particularly related to the roles of a key immune chaperone gp96 (known also as grp94) in the endoplasmic reticulum. A leader in the field of gp96/grp94 chaperone, Dr. Li established its roles in immunity, development, and cancer by advancing the knowledge of its client network, structure-function relationship, and with co-chaperone CNPY3. He also uncovered involvement of the TGF-β-GARP axis and platelets in cancer immune tolerance and discovered CNPY2 as a key initiator of the unfolded protein response. Supported by multiple active NIH grants, Dr. Li’s lab currently focuses on developing better immunotherapeutics against cancer via understanding and reprogramming the tolerogenic tumor microenvironment. His lab has also broadened its interests toward the areas of platelet biology in cancer immune tolerance; understanding the immunological properties of heat shock proteins (HSPs) in cancer immunotherapy, innate immunity, and immune tolerance; regulatory T cells; and the unfolded protein response in inflammation and cancer. He is an elected member of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). Ira Mellman, PhD Genentech Dr. Mellman is Vice President of Cancer Immunology at Genentech, having previously served on the Yale University School of Medicine faculty as department chair, a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology & Immunobiology. Dr. Mellman is a graduate of Oberlin and Yale, and performed postdoctoral work with Ralph Steinman at Rockefeller University. He is a member of the National Academy of Sciences, American Academy of Arts & Sciences, EMBO, and the American Association for Cancer Research Board of Directors. Dr. Mellman’s laboratory is known for advances in cell biology (including the discovery of endosomes) and for applying these insights to understanding the immune response. Of particular importance have been the elucidation of how dendritic cells initiate immunity or maintain immune tolerance, forming the basis for modern efforts in cancer vaccines. Other notable advances include demonstrating how T cell signaling is regulated by the PD-L1/PD-1 pathway, the basis of immune heterogeneity in cancer, and the conceptualization of the cancer immunity cycle. Dr. Mellman is responsible for having brought Genentech’s anti-PD-L1 antibody Tecentriq® (atezolizumab; now a marketed product) to the clinic. He also directed the discovery and early development of tiragolumab (anti-TIGIT; now in pivotal studies), iNeST-RNA (in collaboration with BioNTech; now in Phase II), cobimetinib (MEK inhibitor), mosunetuzumab (CD20-CD3 bispecific antibody), and ipatasertib (Akt inhibitor), among others. Recent awards include Yale’s highest honor, the Wilbur Cross medal, and the 2019 Leadership Award in Cancer Immunology from the American Association for Precision Medicine. SPEAKERS Daniel S. Peeper, PhD Netherlands Cancer Institute Dr. Peeper is professor in Functional Oncogenomics VU University Amsterdam, heading the Department of Molecular Oncology & Immunology and chairing the Research Faculty Council Board at the Netherlands Cancer Institute (NKI). He set up and chaired the Translational Research Board at NKI (2014-1019). He studied Medical Biology at the VU University Amsterdam and received his PhD in the laboratory of Alex van der Eb (Leiden, 1994) for his work on adenovirus oncoproteins and cell cycle proteins. He received his postdoctoral training in the lab of Mark Ewen (Dana-Farber Cancer Institute, Harvard Medical School, Boston) and subsequently the lab of René Bernards (NKI). Previous highlights include his discoveries using functional genetics of a new metastasis gene (Nature 2004); that oncogene-induced cellular senescence (OIS) serves as a tumor suppressor mechanism limiting cancer progression in humans (Nature 2005; New Engl J Med 2006); that OIS is associated with the activation of an inflammatory transcriptome (Cell 2008; Nat Rev Cancer 2009; Genes Dev 2010); that PTEN reduction acts as an OIS bypass mechanism driving melanoma development (Genes Dev 2012); and that pyruvate dehydrogenase kinase (PDK1) acts as a critical switch for the execution of OIS (Nature 2013). His team uses function-based genetic screens to develop rational combinatorial cancer treatment, targeting both cancer and immune cells. They discovered a new mechanism mediating resistance to targeted therapy in melanoma involving the receptor tyrosine kinase AXL (Nature Comm. 2014) and established a large melanoma PDX platform with which they identified a novel resistance mechanism to BRAF inhibition (Cell Rep. 2016). Building on this finding, his laboratory developed a new rational concept for combinatorial targeting of intratumor heterogeneity, which is currently explored clinically (Nature Med. 2018). His group also dissected the mechanism of cancer drug addiction and provided PoC of how this vulnerability may be used clinically (Nature 2017). Most recently, his laboratory has been developing rational cancer treatment, combining tumor and immune cell interventions. Focusing on the interface between tumor and immune cells, his team discovered that lowering the TNF threshold sensitizes tumors to T cell attack and
Load more

Recommended publications
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • Speaker Bios
    Moores UCSD Cancer Center Industry/Academia Translational Oncology Symposium Speaker Bios David R. Bentley, D.Phil. Vice President & Chief Scientist, Illumina, Inc. David Bentley, Ph.D., is Chief Scientist for Illumina’s Sequencing business. His major research interest is the study of human sequence variation. He was previously Head of Human Genetics and founding member of the Board of Management at the Wellcome Trust Sanger Institute where he played leading roles in the Institute’s contribution to the human genome referencing sequence, the SNP Consortium and the International HapMap Project. Dr. Bentley earned a degree in Natural Sciences from the University of Cambridge, took a DPhil at the University of Oxford, and is currently a Fellow of the Academy of Medical Sciences. Clara D. Bloomfield, M.D. Distinguished University Professor William G. Pace III Professor of Cancer Research Cancer Scholar and Senior Advisor, Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute Education &Academic Appointments: 1968 M.D. U Chicago; 1973-80, Assistant, Associate Prof. of Medicine, U Minnesota (U. MN), Minneapolis, MN; 1980-89 Prof. of Medicine, Div. of Oncology, U.MN; 1989-97 Prof. of Medicine & Chief, Div. of Oncology, State University of NY at Buffalo; 1989-97 Chair, Department of Medicine, Roswell Park Cancer Institute (RPCI), Buffalo, NY; 1997-2001 Director, Div. of Hematology & Oncology, Department of Internal Medicine, The Ohio State University College of Medicine & Public Health (OSU COMPH), Columbus, OH; 1997- William G. Pace III Endowed Chair in Cancer Research & Prof, OSU; 1997-2003 Director, Comprehensive Cancer Center (CCC) & Deputy Director, James Cancer Hospital & Solove Research Institute (JCH), OSU; 2003- Cancer Scholar & Senior Advisor, OSUCCC & JCH; 2006- Distinguished University Prof.
    [Show full text]
  • Appendix 1*) for Essential Information Very Well Illustrated in Google and Wikipedia
    Appendix 1*) For Essential Information Very Well Illustrated in Google and Wikipedia *) in Support of the Text with Literature Citations. Referrals to illustrations in Appendix 2. Cancer in the Plant. The insertion of the Agrobacterium tumefaciens circular plasmid T (transferred) DNA into the genome of its new host, the plant (Gelvin BS. Microbiol Molecular Biol Rev 2003;67:16–37). The plant cancer “crown gall” (agrocallus; Agrobacterial crown gall) consists of malignantly transformed cells replicating the agrobacterial T DNA plasmid (reviewed in postscript Table XXXV). For reference: Koncz C Mayerhofer R Koncz-Kálmán Zs et al EMBO J 1990;9:1337–1346. Transfer of potentially oncogenic bacterial genes and proteins to patients: Septicemic Bacteroides enterotoxigenic (Sinkovics J G & Smith JP Cancer 1970;25:663–671; Viljoen KS et al PLoS One 2015;10(3):e0119462); Bartonella bacilliformis etc (Guy L et al PLoS Genet 2013;9(3):e1003393; Harms A & Dehio C Clin Microbiol Rev 2012;25:42–78; Llosa M et al Trends Microbiol 2012;20:355–9; Minnick MF et al PLoS Negl Trop Dis 2014;6(7):e2919); Helicobacter pylori (Bonsor DA et al J Biol Chem 2015;pii:jbc.M115.641829; Su YL et al J Immunol 2015;194:3997–4007; Vaziri F et al Pathog Dis 2015;73(3). pii.ftu021); Porphyromonas gingivalis (Katz J et al Int J Oral Sci 2011;3:209–215); Tuberculous infections with A. tumefaciens in patients (Ramirez FC et al Clin Infect Dis 1992;15:938–940). DNA-binding Antibodies. DNA- (or RNA-) binding proteins use zink finger motifs, leucine zippers and winged (beta-sheet loops) helix-turn helix motifs (HTH, two helices separated by the loop, RNA/DNA-binding domains) in recognition of RNA/DNA receptors for attachment.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • AACR Settles Dispute with Toronto Hotels Over 2003 Annual Meeting
    Vol. 31 No. 15 April 15, 2005 © Copyright 2005 The Cancer Letter Inc. All rights reserved. Price $335 Per Year AACR Settles Dispute With Toronto Hotels Over 2003 Annual Meeting Cancellation By Kirsten Boyd Goldberg The American Association for Cancer Research has settled a legal dispute with the Toronto Convention Center and hotels, stemming from the AACR 2003 Aftermath: cancellation of its annual meeting in April 2003. NCI Provided $2 Million The convention center and 19 hotels sought $6.2 million Canadian To Pay Washington from AACR as payment under contracts for housing the estimated 16,000 Convention Center, scientists and others who were expected to attend the meeting. Other Expenses Two days before the event was scheduled to begin, AACR cancelled . Page 2 it, citing the outbreak of Severe Acute Respiratory Syndrome in Toronto. (Continued to page 2) Washington Roundup: In Brief: Senate Committee AACR To Honor Eight Scientists Delays Session At Annual Meeting In Anaheim On FDA Nominee The American Association for Cancer Research will honor several . Page 4 scientists at its annual meeting April 16-20, in Anaheim, Calif. David Livingston, deputy director, Dana-Farber/Harvard Cancer Center National Academies: and the Emil Frei Professor of Genetics and Medicine, Harvard Medical Report Defines School, will receive the AACR-G.H.A. Clowes Memorial Award for his Indicators Of Progress contributions to the understanding of the molecular basis of cancer. In Quality of Care Charles Sawyers, investigator, Howard Hughes Medical Institute and . Page 5 Peter Bing Professor of Medicine, University of California, Los Angeles, will be awarded the AACR-Richard and Hinda Rosenthal Foundation Award Oversight Needed for his research in molecularly-targeted therapy, with special emphasis on For Cord Blood Banks, signaling pathway abnormalities in cancer cells as targets for drug therapy.
    [Show full text]
  • A Tribute to Emil Frei III
    Obituary A tribute to Emil Frei III Dr. Emil Frei III, one of the fathers of be found) was opposed by Abraham Goldin combination chemotherapy for cancer, and Lloyd Law at the NCI as well as Howard died after a prolonged illness in May of Skipper and Frank Schabel at the Southern 2013. He was 89 years old (Figure 1). Research Institute in Alabama, who were Known to his colleagues, family, and experts in the drug treatment of leukemic friends as Tom, Frei was the emeritus cell lines and murine leukemia. They held director and emeritus physician-in-chief that combinations of drugs with different of the Dana-Farber Cancer Institute and targets given simultaneously provided the the Richard and Susan Smith Distin- only hope for sustained remissions, since guished Professor of Medicine emeritus most cancers have infinite ways of finding at Harvard Medical School. A highly dis- their way around single agents. Zubrod, tinguished clinical investigator, Frei held whose military medicine experience was in leadership positions of major responsibil- the malaria program of World War II, saw ity at the National Cancer Institute (NCI) childhood leukemia as the cancer equiva- in Bethesda, Maryland, and at the M.D. lent of malaria and agreed with the basic Anderson Cancer Center in Houston, scientists. He urged Frei and Freireich to Texas, before his appointment at Harvard. combine drugs as they were produced to Frei was born in St. Louis on February 21, treat leukemia in childhood, to collaborate 1924, where his paternal grandfather had with other like-minded physicians, and to founded Emil Frei and Associates, a well- train younger physicians to learn the new known stained glass company.
    [Show full text]
  • A History of Cancer Chemotherapy Vincent T
    AACR Centennial Series A History of Cancer Chemotherapy Vincent T. DeVita, Jr. and Edward Chu Yale Cancer Center, Yale University School of Medicine, New Haven Connecticut Abstract The Early Period of Cancer Drug Development The use of chemotherapy to treat cancer began at the start of A selected history and timeline of events related to the the 20th century with attempts to narrow the universe of development of cancer chemotherapy is shown in Fig. 1. The first chemicals that might affect the disease by developing methods four decades of the 20th century were primarily devoted to model to screen chemicals using transplantable tumors in rodents. development. The major limitations of drug discovery were two- It was, however, four World War II–related programs, and the fold: first, the development of models that could effectively be used effects of drugs that evolved from them, that provided the to reduce the vast repertoire of chemicals to those few that might impetus to establish in 1955 the national drug development have activity against cancer in humans, and second, the access to effort known as the Cancer Chemotherapy National Service clinical facilities to test such agents. Center. The ability of combination chemotherapy to cure acute A major breakthrough in model development occurred in the early childhood leukemia and advanced Hodgkin’s disease in the 1910s when George Clowes of Roswell Park Memorial Institute (RPMI) 1960s and early 1970s overcame the prevailing pessimism about in Buffalo, New York, Roswell Park Memorial Institute developed the the ability of drugs to cure advanced cancers, facilitated the first transplantable tumor systems in rodents.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • Emil Freireich, MD
    Emil Freireich, MD Session 1—October 5, 2011 About transcription and the transcript This interview had been transcribed according to oral history best practices to preserve the conversational quality of spoken language (rather than editing it to written standards). The interview subject has been given the opportunity to review the transcript and make changes: any substantial departures from the audio file are indicated with brackets [ ]. In addition, the Archives may have redacted portions of the transcript and audio file in compliance with HIPAA and/or interview subject requests. The views expressed in this interview are solely the perspective of the interview subject. They are not to be interpreted as the official view of any other individual or of The University of Texas MD Anderson Cancer Center. Chapter 00A Interview Identifier Tacey Ann Rosolowski, PhD 0:00:10.6 I am Tacey Ann Rosolowski, interviewing Dr. Emil J Freireich. It’s Emil, correct? Emil J Freireich, MD 0:00:17.8 Americans say “ee.” Tacey Ann Rosolowski, PhD 0:00:21.7 How would you like me to say it? Emil J Freireich, MD 0:00:23.1 J. 1 Interview Session: 01 Interview Date: October 5, 2011 Tacey Ann Rosolowski, PhD 0:00:23.4 J Freireich at the University of Texas MD Anderson Cancer Center in Houston, Texas. This interview is being conducted for the Making Cancer History Voices Oral History Project, run by the Historical Resources Center at MD Anderson. Dr. Freireich holds the Ruth Harriet Ainsworth Chair in Developmental Therapeutics. He is also a distinguished teaching professor and director of special medical education programs as well as the director of the Adult Leukemia Research Program at the University of Texas MD Anderson Cancer Center.
    [Show full text]
  • A Tribute to Emil Frei III
    A tribute to Emil Frei III Edward J. Benz Jr., David G. Nathan J Clin Invest. 2013;123(8):3188-3189. https://doi.org/10.1172/JCI71579. Obituary Dr. Emil Frei III, one of the fathers of combination chemotherapy for cancer, died after a prolonged illness in May of 2013. He was 89 years old (Figure 1). Known to his colleagues, family, and friends as Tom, Frei was the emeritus director and emeritus physician-in-chief of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor of Medicine emeritus at Harvard Medical School. A highly distinguished clinical investigator, Frei held leadership positions of major responsibility at the National Cancer Institute (NCI) in Bethesda, Maryland, and at the M.D. Anderson Cancer Center in Houston, Texas, before his appointment at Harvard. Frei was born in St. Louis on February 21, 1924, where his paternal grandfather had founded Emil Frei and Associates, a well-known stained glass company. He attended St. Louis University and then joined the United States Navy in World War II. The Navy sent him to Colgate University and then to Yale University for medical training. He graduated from Yale Medical School in 1948 and later served in the Navy Medical Corps during the Korean War. In 1955, Frei and his close colleague Emil J. Freireich were recruited to the expanding clinical program at the NCI by Gordon Zubrod, then the newly appointed NCI clinical director. Supported by Zubrod’s superb guidance and defense, Frei and Freireich began their […] Find the latest version: https://jci.me/71579/pdf Obituary A tribute to Emil Frei III Dr.
    [Show full text]
  • Emil J. Freireich: Legend in Cancer Research (March 16, 1927–February 1, 2021)
    Bone Marrow Transplantation (2021) 56:1764–1767 https://doi.org/10.1038/s41409-021-01284-z OBITUARY Emil J. Freireich: Legend in cancer research (March 16, 1927–February 1, 2021) Hagop Kantarjian 1 Received: 1 March 2021 / Revised: 3 March 2021 / Accepted: 24 March 2021 / Published online: 13 May 2021 © The Author(s), under exclusive licence to Springer Nature Limited 2021 Emil J. Freireich was a trailblazing scientist and the founding father of modern cancer research and care. To many of us who knew him well, he was much more: an idol and hero, a daily inspirational role model, a mentor and often a third parent. As he did for hundreds of us, Freireich brought me from a distant country to the United States when I was a 24-year-old medical student for a 4-month elective rotation, then in 1981 as a fellow. He took us under his wing 1234567890();,: 1234567890();,: at the University of Texas MD Anderson Cancer Center, provided us with endless opportunities, and helped us become, for better or for worse, who we are today. President Obama’s book title “The Audacity of Hope” describes the two salient characteristics that define the arc of his life and career. Freireich was first and foremost infinitely hopeful and optimistic. He said: “Humans cannot live without hope. Hopelessness is the greatest trauma a person has to suffer.” He knew this firsthand, having been born in 1927 under merciless conditions in Chicago, and having lost his father when he was 2. In his 1997 oral history (preserved at the National Cancer Institute [NCI]), he said, “People born in that era are a special brand of people because they lived through one of the greatest economic dislocations in the history of our species—the Great Depression of 1929….
    [Show full text]
  • August 21, 2019 Oversight Committee Meeting Packet
    Oversight Committee Meeting August 21, 2019 Oversight Committee Meeting Agenda Texas State Capitol Extension 1100 Congress Avenue, Austin, Texas 78701 Room E1.012 August 21, 2019 9:00 a.m. The Oversight Committee may discuss or act on any item on this agenda, and as authorized by the Texas Open Meetings Act, Texas Government Code Section 551.001 et seq., may meet in closed session concerning any purpose permitted by the Act. Anyone wishing to offer public comments must notify the Chief Executive Officer in writing prior to the start of the meeting. The Committee may limit the time a member of the public may speak. 1. Call to Order 2. Roll Call/Excused Absences 3. Adoption of Minutes from the May 15, 2019 meeting Tab 1 4. Public Comment 5. Grantee Presentation Tab 2 6. Chief Executive Officer Report Tab 3 7. Chief Compliance Officer Report and Compliance Certification of Grant Award Process Tab 4 8. Chief Scientific Officer Report Tab 5 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications 9. Chief Product Development Officer Report Tab 6 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications • Product Development Review Council Membership • DP180042 contract change request • DP170043 contract change request 10. Chief Prevention Officer Report Tab 7 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications 11. Internal Auditor Report Tab 8 • Internal Audit Follow Up Procedures Report Over Procurement and P-Cards • FY 2020 Internal Audit Plan 12. Scientific Research and Prevention Program Committee Appointments Tab 9 13. Advisory Committee Appointments Tab 10 14.
    [Show full text]